SSU72L2: A Potential Drug Target and Biomarker (G390031)

Target Name: SSU72L2

NCBI ID: G390031

SSU72L2

Other Name(s): SSU72P2 | SSU72 RNA polymerase II CTD phosphatase homolog pseudogene 2 | SSU72 pseudogene 2 | SSU72 like 2

SSU72L2: A Potential Drug Target and Biomarker

Introduction

Sodium channels play a crucial role in the function of various physiological processes in the body. In particular, they are involved in the regulation of neural and muscle activity. The sodium channel subfamily AI (alpha-1) is one of the most well-studied families of channels, and its function is crucial for normal brain function. The gene encoding for SSU72L2 (Sodium Channel Union72-Like2), a member of the AI 鈥嬧?媐amily, has been well-described in the scientific literature. This article will provide an overview of SSU72L2 as a drug target and biomarker.

Structure and Function

SSU72L2 is a single-transmembrane protein that contains a N-terminus, a catalytic C-terminus, and a C-terminal region that is involved in interactions with other channels. Its structure is similar to that of other 伪1 channels, with a complex organization of multiple transmembrane 伪-helices and 尾-sheets.

Function

SSU72L2 is involved in the regulation of a wide range of physiological processes, including neuronal and muscle activity. It is highly expressed in the brain and is also found in other tissues, such as heart, pancreas, and muscle. It plays a crucial role in the regulation of neurotransmitter release, as well as in the maintenance of the resting membrane potential.

Drug Target

The potential drug targets for SSU72L2 are numerous. Its involvement in the regulation of neural and muscle activity makes it an attractive target for drugs that aim to modulate these processes. One of the main drug targets for SSU72L2 is the treatment of epilepsy, a neurological disorder that is characterized by the recurrence of epileptic seizures.

In recent years, several inhibitors of SSU72L2 have been developed and have been shown to be effective in animal models of epilepsy. One such drug is topiramate, which is an inhibitor of ion channels, including those involved in epilepsy. Topiramate has been shown to reduce the frequency and severity of epileptic seizures in animal models of epilepsy.

Another potential drug target for SSU72L2 is the regulation of pain. SSU72L2 is involved in the regulation of pain perception and has been shown to play a role in the development of neuropathic pain. Therefore, inhibitors of SSU72L2 have been shown to be effective in the treatment of neuropathic pain.

Biomarker

SSU72L2 has also been shown to be a potential biomarker for various neurological disorders, including epilepsy and pain. The levels of SSU72L2 have been shown to be altered in the brains of individuals with epilepsy and in individuals experiencing neuropathic pain. Therefore, SSU72L2 may be used as a biomarker for these disorders and could be targeted by drugs that aim to modulate these processes.

Conclusion

In conclusion, SSU72L2 is a well-studied protein that is involved in the regulation of a wide range of physiological processes, including neuronal and muscle activity. Its potential drug targets and biomarkers make it an attractive target for the development of new treatments for a variety of neurological disorders. Further research is needed to fully understand the functions of SSU72L2 and its potential as a drug.

Protein Name: SSU72 Like 2

The "SSU72L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SSU72L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets